Alternatives to Hims & Hers

The brand-access marketplace: real FDA-approved pens and oral options with insurance-style navigation — but a required video visit, a 28-day billing cycle, and prices that sit well above the compounded field.

RxSpan MD is a genuinely well-disclosed service wrapped in marketing that undercuts it. The disclosure: four compounding pharmacies named with phone numbers, two lead physicians named with NPI numbers that verify as active MDs, flat pricing posted before any intake, both compounded and real FDA-approved brand GLP-1s on one platform, and oral capsules for anyone who won't inject. Compounded semaglutide is $249 a month and tirzepatide $329, with brand Zepbound at $1,069, Ozempic at $1,299 and Wegovy at $1,349. The marketing is the problem. Its testimonials still name a different company — one patient describes what she 'expected from CareGLP' — and the doctors quoted in them are not the clinicians the same page names as its medical team. The homepage is built around a board-certified plastic surgeon who founded the practice but is licensed in California only and isn't the prescriber. Its compounded prices also sit above the roster median, and the oral capsules cost the same or more than the injections.

$99/mo semaglutide, $183/mo tirzepatide, all 50 states, a named physician personally reviewing every intake, and a real 5-7 day timeline — on a broader peptide platform where GLP-1 pricing is genuinely invisible unless you know to pull the page's own data bundle.

AskRx solves the pricing question most of this page leaves open, and creates a different one. Its care fee is itemized in its own footnote — $90/month physician visit, $10/month fulfilment, $100 total — and the medication is billed separately through its own pharmacy, at cost, with both halves shown at checkout. If you have ever wondered how much of a blended monthly price is the drug and how much is margin, this is the provider that answers it. It is FDA-approved only ('No compounded meds'), so the options are the Wegovy pen, the Wegovy pill, Zepbound in pen or KwikPen form, and Foundayo, the oral tirzepatide. All 50 states, board-certified physicians with obesity-medicine training, unlimited messaging, monthly titration, cancel anytime. Two logistics notes that matter on a workday. First, $100 is a floor: no medication price is published, so your real monthly total is unknown until checkout and depends on coverage. Second — and read this one if scheduling is your constraint — 'video visits available in select states' means the async route is not universal here, so confirm your own state before assuming you can do this without a call.

The sum is transparent and it is the seller's own: $99 a month for the service, plus the manufacturer's charge — $299 for the Zepbound starter pen, $149 for the Wegovy pill — giving $398 and $248. The first month is $25 instead of $99. Both of those manufacturer figures are LillyDirect's and NovoCare's own, so the arithmetic can be checked from outside, and it holds. What is not published is the ladder as your dose climbs.

A sublingual (under-the-tongue), not injectable, GLP-1 program — $189/mo semaglutide and $319/mo tirzepatide on a 6-month prepay plan, $209/mo and $359/mo on a shorter 2-month plan — serving 34 states plus DC.

One flat $195/mo plan covers compounded semaglutide, compounded tirzepatide, or a needle-free sublingual option — plus real brand-name access if you want an FDA-approved pen instead — with a women's-health-first framing and a $99 first month, though it won't name your state until you're inside the signup flow.

The manufacturer's own channel for brand Wegovy — $149/mo self-pay or as low as $25/mo with commercial insurance — but it requires your own existing prescription and offers no tirzepatide, since that's a different company's drug.

An established longevity-telehealth brand with a microdose-first GLP-1 menu — starting at $99/mo microdosing semaglutide, $159/mo microdosing tirzepatide — plus brand-name Wegovy/Zepbound access-and-monitoring for a separate $50–$65 fee (drug cost billed apart).